报告揭示了美国低收入和少数民族病人在获得减重药物方面存在的经济和种族差距。 Report reveals economic and racial disparity in access to weight-loss drugs for low-income and minority patients in the US.
《华盛顿邮报》的一份报告揭示了在获得减重药物方面存在的经济和种族差距,特别是在低收入社区以及美国黑人和西班牙裔病人之间。 A report by The Washington Post reveals an economic and racial disparity in access to weight-loss drugs, particularly among low-income neighborhoods and Black and Hispanic patients in the US. 尽管这些群体更有可能患肥胖症和2型糖尿病,但由于财政障碍和缺乏保险,他们不太可能成为奥泽姆皮奇和穆恩贾罗等处方减重药物。 Despite these groups being more likely to suffer from obesity and type 2 diabetes, they are less likely to be prescribed weight-loss drugs like Ozempic and Mounjaro due to financial barriers and lack of insurance. 研究人员认为,解决健康的社会决定因素,如文化因素和医生的偏见信仰,对于实现平等获得这些药物至关重要。 Researchers suggest that addressing social determinants of health, such as cultural factors and biased beliefs from doctors, is crucial in achieving equal access to these medications.